-
11:42:45 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

SCYX Stock News

05/10/22 8:30 AM
Nasdaq : SCYX
clinical trial
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who were either
RHEA-AI
neutral
04/27/22 8:30 AM
Nasdaq : SCYX
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit specialty hospital.
RHEA-AI
neutral
04/22/22 8:00 AM
Nasdaq : SCYX
clinical trial
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting. Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp into a broad
RHEA-AI
neutral